NCT00097799Approved For Marketing不适用
An Open Label, Non-randomized Treatment Protocol of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Protease Inhibitor-experienced Patients With HIV-1 Infection (the Tipranavir Expanded Access Program)
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 试验地点
- 115
研究概览
简要总结
This study was designed to provide early access to and evaluate the safety of TPV/r in PI-experienced patients with HIV-1 infection.
研究设计
- 研究类型
- Expanded Access
入排标准
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (115)
Loading locations...
相似试验
已完成
1 期
Phase I Study on VEGF Vaccination in Metastatic Solid TumorsMetastatic CancerNCT02237638Amsterdam UMC, location VUmc30
进行中（未招募）
1 期
PEP on a Skin Graft Donor Site WoundSkin GraftNCT04664738Rion Inc.8
已完成
1 期
Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b ParticipantsChronic Hepatitis C InfectionNCT01700179Alexion Pharmaceuticals, Inc.8
已完成
4 期
Rigorous Assessment of P. Vivax Relapses and Primaquine Efficacy for Radical CureVivax MalariaNCT04706130University of Maryland, Baltimore160
已完成
1 期
A Study of HRS-9057 in Patients With Heart Failure and Volume OverloadHeart Failure With Volume OverloadNCT06506994Fujian Shengdi Pharmaceutical Co., Ltd.25